Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on developing new therapies for patients with central and peripheral nervous system disorders. Its product Xadago®/safinamide has received marketing authorization for the treatment of Parkinson's disease in the EU, Switzerland, the UK, the US, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea, and is commercialized by Newron's partner Zambon.